




RECEIVED
MAY 30 2002
TECH CENTER 1600/2900

In re Application of: Goeddel and Rothe
 Serial No. 08/779,599
 Filed On January 7, 1997
 Mailed On: 8 October 1997

Docket No.: P0897C2
 By: Ginger R. Dreger
 Reg No. 33,055

The following has been received in the U S Patent Office on the date stamped

<input checked="" type="checkbox"/> Communication/Transmittal (dup)	<input type="checkbox"/> Notice To File Missing Parts (copy)
<input type="checkbox"/> Extension of Time Request (dup)	<input type="checkbox"/> Declaration/Power of Atty
<input checked="" type="checkbox"/> Amendment/Response	<input type="checkbox"/> Assignment
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Recodation Form
<input type="checkbox"/> Form 1449 with ___ References	<input type="checkbox"/> Drawings: ___ Sheets
<input type="checkbox"/> Notice of Appeal (dup)	<input type="checkbox"/> Informal ___ Formal
<input type="checkbox"/> Issue Fee Transmittal Form	<input type="checkbox"/> Certificate re: Sequence Listing
<input checked="" type="checkbox"/> Certificate of Mailing	<input type="checkbox"/> Sequence Listing & Diskette
<input type="checkbox"/> Certificate of Express Mailing	<input type="checkbox"/> Fees: \$ ___
<input type="checkbox"/> Express Mail Label No.:	<input type="checkbox"/> Other: ___



Patent Docket P0897C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Goeddel and Rothe Serial No.: 08/779,599 Filed: January 7, 1997 For: TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS	Group Art Unit: 1812 Examiner: J. ULM <div style="text-align: center;"> <small>CERTIFICATE OF MAILING</small> <small>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231 on</small> October 8, 1997 <i>Aida A. Miclar</i> Aida A. Miclar </div>
---	--

RECEIVED

MAY 30 2002

TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

BOX NON-FEE AMENDMENT
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	4	-	20	0	x 22 =	\$0 00
Independent	4	-	3	0	x 82 =	\$0.00
— 0					+ 270 =	\$0.00
Total Fee Calculation						\$0.00

 X

No additional fee is required.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630
in the amount of \$. A duplicate copy of this transmittal is enclosed.
Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17,
or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: October 8, 1997

By: *[Signature]*
Ginger R. Dreger
Reg. No. 33,055

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-3216
Fax: (650) 952-9881

RECEIVED

MAY 30 2002

TECH CENTER 1600/2900
Patent Docket P0897C2#9/5
ms
06/04/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Goeddel and Rothe Serial No.: 08/779,599 Filed: January 7, 1997 For: TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS	Group Art Unit. 1812 Examiner: J. ULM CERTIFICATE OF MAILING I hereby certify that the correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on October 8, 1997 <i>Aida A. Miclat</i> Aida A. Miclat
---	--

AMENDMENT UNDER 37 C.F.R. §1.111BOX NON-FEE AMENDMENT
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This is in response to the Office Action mailed July 8, 1997 (Paper No. 6) setting a three months term.

Kindly amend this application in the following aspects.

In the Specification:

In the first sentence, after the title, please delete "which application(s) is(are) incorporated herein by reference and".

In the Claims:

Please amend claim 31 as follows:

131. (Amended) An isolated human tumor necrosis factor receptor associated factor (TRAF) [encoded by] prepared by

142

C